Figure 4.
Figure 4. Flow cytometric analyses of tumors and spleens. (A) Flow cytometric analysis of tumors in anti–TGF-β (right column)–and control-treated (left column) hu PBL-SCID mice. The hu PBL-SCID mice were injected with 100 μg anti–TGF-β (A411) or mouse IgG every other day for 9 weeks. At harvest, tumors were analyzed by flow cytometry for the presence of human B cells and T-cell expansion and activation. Data are shown from a representative animal in each group (n = 5 mice/group). (B) Flow cytometric analysis of spleens from anti–TGF-β (right column)–and control-treated (left column) hu PBL-SCID mice. The hu PBL-SCID mice were given injections of 100 μg anti–TGF-β (A411) or mouse IgG every other day for 9 weeks. At harvest, spleens were analyzed by flow cytometry for the presence of human B cells and T-cell expansion and activation. Data are shown from a representative animal in each group (n = 5 mice/group).

Flow cytometric analyses of tumors and spleens. (A) Flow cytometric analysis of tumors in anti–TGF-β (right column)–and control-treated (left column) hu PBL-SCID mice. The hu PBL-SCID mice were injected with 100 μg anti–TGF-β (A411) or mouse IgG every other day for 9 weeks. At harvest, tumors were analyzed by flow cytometry for the presence of human B cells and T-cell expansion and activation. Data are shown from a representative animal in each group (n = 5 mice/group). (B) Flow cytometric analysis of spleens from anti–TGF-β (right column)–and control-treated (left column) hu PBL-SCID mice. The hu PBL-SCID mice were given injections of 100 μg anti–TGF-β (A411) or mouse IgG every other day for 9 weeks. At harvest, spleens were analyzed by flow cytometry for the presence of human B cells and T-cell expansion and activation. Data are shown from a representative animal in each group (n = 5 mice/group).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal